Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Emergent BioSolutions has partnered with the Mount Sinai Health System and ImmunoTek Bio Centers for the development, manufacture and clinical testing of its Covid-19 hyperimmune globulin candidate, COVID-HIG.
As part of the collaboration, the partners will conduct post-exposure prophylaxis (PEP) study in health care providers at high risk of contracting Covid-19, along with other high-risk populations.
The study will be backed by $34.6m funding support from the US Department of Defense (DOD)’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).